The Role of Perioperative Anti-VEGF During Vitrectomy for Vitreous Hemorrhage in Relation to Postoperative Nonclearing Vitreous Hemorrhage and Cystoid Macular Edema

Abstract

Purpose:

To assess the role of perioperative anti–vascular endothelial growth factor (anti-VEGF) on the incidence of rebleed and foveal thickness in patients undergoing pars plana vitrectomy (PPV) for nonclearing vitreous hemorrhage due to retinal vascular disorders.

Design:

Retrospective, randomized, comparative interventional study.

Methods:

Three hundred twelve eyes were assigned to group A (eyes undergoing PPV without anti-VEGF, n = 165) and group B (eyes undergoing PPV with anti-VEGF, n = 147) and were followed up for a minimum of 6 months. The incidence of rebleed and 1 month postoperative central foveal thickness (CFT) was recorded and analyzed.

Results:

The incidence of postoperative vitreous hemorrhage (POVH) in group A was 21.81%, which was significantly (P = .025) higher than in group B (12.24%). Mean CFT in group A (289.24 ± 49.47 μm) was higher as compared to group B (263.42 ± 94.42), but the difference was not statistically significant.

Conclusion:

Perioperative intravitreal anti-VEGF given at the end of the surgery significantly reduces the incidence of POVH and helps in achieving better CFT postoperatively.

Keywords

nonclearing vitreous hemorrhage postoperative vitreous hemorrhage perioperative anti-VEGF vitrectomy for nonclearing vitreous hemorrhage vitreous hemorrhage POVH anti-VEGF.

Get full access to this article

View all access options for this article.

References

Spraul

Grossniklaus

. Vitreous hemorrhage. Surv Ophthamol. 1997;42(1):3–39.

Saxena

Jalali

Verma

Pathengay

. Management of vitreous hemorrhage. Indian J Ophthalmol. 2003;51(2):189–196.

Spaide

Fisher

. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina. 2006;26(3):275–278.

Joussen

Wolfensberger

. Mechanisms of macular edema and therapeutic approaches. In: Ryan

, ed. Retina 5th ed. Philadelphia, PA: Elsevier; 2013:593.

Patel

Hykin

Cree

. Diabetic cataract removal: postoperative progression of maculopathy-growth factor and clinical analysis. Br J Ophthalmol. 2006;90(6):697–701.

Sadiq

Chatterjee

Vernon

. Progression of diabetic retinopathy and rubeotic glaucoma following cataract surgery. Eye (Lond). 1995;9(pt 6):728–738.

Stefansson

. Physiology of vitreous surgery. GraefesArch Clin Exp Ophthalmol. 2009;247(2):147–163.

Simo

Carrasco

Garcia-Ramirez

Hernandez

. Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr Diabetes Rev. 2006;2:71–98.

Funatsu

Yamashita

Ikeda

Mimura

Eguchi

Hori

. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology. 2003;110(9):1690–1696.

10.

Yeung

Liu

. Reducing the incidence of early postoperative vitreous hemorrhage by preoperative intravitreal bevacizumab in vitrectomy for diabetic tractional retinal detachment. Acta Ophthalmol. 2010;88(6):635–640.

11.

Ahmadieh

Shoeibi

Entezari

Monshizadeh

. Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial. Ophthalmology. 2009;116(10):1943–1948.

12.

Rizzo

Genovesi-Ebert

Di Bartolo

Vento

Miniaci

Williams

. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol. 2008;246(6):837–842.

13.

Modarres

Nazari

Falavarjani

Naseripour

Hashemi

Parvaresh

. Intravitreal injection of bevacizumab before vitrectomy for proliferative diabetic retinopathy. Eur J Ophthalmol. 2009;19(5):848–852.

14.

El-Batarny

. Intravitreal bevacizumab as an adjunctive therapy before diabetic vitrectomy. Clin Ophthalmol. 2008;2(4):709–716.

15.

Romano

Gibran

Marticorena

Wong

Heimann

. Can a preoperative bevacizumab injection prevent recurrent postvitrectomy diabetic vitreous haemorrhage? Eye (Lond). 2009;23(8):1698–1701. doi:10.1038/eye.2008.354.

16.

Romano

Gibran

Marticorena

Wong

Heimann

. Can an intraoperative bevacizumab injection prevent recurrent postvitrectomy diabetic vitreous hemorrhage? Eur J Ophthalmol. 2009;19(4):618–621.

17.

Park

Shin

Kim

. Intravitreal injection of bevacizumab and triamcinolone acetonide at the end of vitrectomy for diabetic vitreous hemorrhage: a comparative study. Graefes Arch Clin Exp Ophthalmol. 2010;248(5):641–650.

18.

Ahn

Woo

S J

Chung

Park

. The effect of adjunctive intravitreal bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy. Ophthalmology. 2011;118(11):2218–2226.

19.

Smith

Steel

. Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy. Cochrane Database Syst Rev. 2011;(5):CD008214.

20.

Cheema

Mushtaq

Al Khars

. Role of intravitreal bevacizumab (Avastin) injected at the end of diabetic vitrectomy in preventing postoperative recurrent vitreous hemorrhage. Retina. 2010;30(10):1646–1650.

21.

Funatsu

Yamashita

Noma

. Outcome of vitreous surgery and the balance between vascular endothelial growth factor and endostatin. Invest Ophthalmol Vis Sci. 2003;44(3):1042–1047.

22.

Funatsu

Yamashita

Mimura

Noma

Nakamura

Hori

. Risk evaluation of outcome of vitreous surgery based on vitreous levels of cytokines. Eye (Lond). 2007;21(3):377–382.

23.

Stefansson

The therapeutic effects of retinal laser treatment and vitrectomy. A theory based on oxygen and vascular physiology. Acta Ophthalmol Scand. 2001;79(5):435–440.

24.

Di Lauro

De Ruggiero

di Lauro

Romano

. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2010;248(6):785–791. doi:10.1007/s00417-010-1303-3.

25.

Zhang

Liu

Hernandez-Da Mota

. Vitrectomy with or without preoperative intravitreal bevacizumab for proliferative diabetic retinopathy: a meta-analysis of randomized controlled trials. Am J Ophthalmol. 2013;156(1):106–115.e2. doi:10.1016/j.ajo.2013.02.008.

26.

Sawada

Kawamura

Kakinoki

Sawada

Ohji

. Vascular endothelial in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy. Arch Ophthalmol. 2007;125(10):1363–1366.

27.

Oshima

Shima

Wakabayashi

. Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment. Ophthalmology. 2009;l16(5):927–938.

28.

da R Lucena

Ribeiro

Costa

. Intraoperative bleeding during vitrectomy for diabetic fractional retinal detachment with versus without preoperative intravitreal bevacizumab (IBeTra study). Br J Ophthalmol. 2009;93(5):688–691.